C-Type Natriuretic Peptide in Essential Hypertension: Old Ways for a New Time

Area of Science:

• Cardiovascular Pharmacology
• Endocrinology
• Vascular Biology

Background:

• Essential hypertension involves multiple mechanisms, including sympathetic nervous system activity, vasoactive mediators, vascular inflammation, and fibrosis.
• Current antihypertensive drugs target these pathways, but novel therapeutic approaches are needed.
• C-type natriuretic peptide (CNP) is an endothelium-derived peptide with vascular signaling roles via natriuretic peptide receptor-B (NPR-B) and natriuretic peptide receptor-C (NPR-C).

Purpose of the Study:

• To review the effects of CNP on the vasculature in the context of essential hypertension.
• To evaluate the potential of targeting the CNP system as a therapeutic strategy for hypertension management.
• To compare the safety profile of CNP-based therapies regarding hypotension risk.

Main Methods:

• Literature review and perspective synthesis.
• Analysis of CNP's vascular signaling pathways and their relevance to hypertension.
• Comparison of CNP with other natriuretic peptides (atrial natriuretic peptide, B-type natriuretic peptide) in terms of therapeutic risk.

Main Results:

• CNP exerts beneficial effects on the vasculature relevant to essential hypertension.
• The CNP system presents a minimal risk of hypotension compared to atrial natriuretic peptide and B-type natriuretic peptide.
• CNP-based therapies are emerging, with modified CNP used for congenital growth disorders.

Conclusions:

• Targeting the CNP system, either through exogenous administration or by modulating endogenous concentrations, is a promising therapeutic strategy for essential hypertension.
• CNP-based interventions may offer a valuable addition to the pharmacological management of long-term hypertension.
• The low risk of hypotension associated with CNP makes it an attractive candidate for chronic antihypertensive therapy.